Gerilimzumab
Gerilimzumab (GB224) is a humanized monoclonal antibody inhibitor targeting interleukin-6 (IL-6) . Gerilimzumab is promising for research of autoimmune diseases such as rheumatoid arthritis[1].
Product Specifications
Product Name Alternative
ARGX-109; GB224; RYI-008
UNSPSC
12352100
Target
Interleukin Related
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
References & Citations
[1]Yan D, et al. Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Gerilimzumab (GB224), a recombinant humanized interleukin-6 monoclonal antibody, in healthy Chinese adults: A randomized controlled dose-escalation study. Expert Opin Investig Drugs. 2023 Feb;32 (2) :161-170.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Isoform
IL-6
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
